GlassScriptPhysician profile
Vanessa Frazier
NPI 1871310011
$1,209.78
in general payments reported to CMS, 2019-2025
11 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $44.40 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.79 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $405.80 | 2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $232.08 | 2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $124.67 | 2025 | |
| Viatris Specialty LLC | $108.49 | 2025 | Yupelri |
| Zoll Respicardia, INC. | $81.20 | 2025 | Remede System |
| Regeneron Healthcare Solutions, INC. | $71.61 | 2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $69.99 | 2025 | |
| Boston Scientific Corporation | $44.40 | 2024 | Accolade Sr |
| Inspire Medical Systems, INC. | $35.19 | 2025 | Inspire |
| Lilly USA, LLC | $20.35 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $16.00 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.